We serve Chemical Name:4-pyrrolidin-3-ylpyridine,hydrochloride CAS:869971-44-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-pyrrolidin-3-ylpyridine,hydrochloride
CAS.NO:869971-44-8
Synonyms:3APX-P04-1;4-Pyrrolidin-3-ylpyridine hydrochloride
Molecular Formula:C9H13ClN2
Molecular Weight:184.66600
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:24.92000
Exact Mass:184.07700
LogP:2.28930
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3APX-P04-1 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Pyrrolidin-3-ylpyridine hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3APX-P04-1 Use and application,4-Pyrrolidin-3-ylpyridine hydrochloride technical grade,usp/ep/jp grade.
Related News: And, while 89 percent of seniors nationwide are now protected by COVID-19 vaccinations, less than 70 percent of the seniors living in underserved communities have been vaccinated to prevent COVID-19 infections, hospitalizations and deaths. We must stay focused on helping the most at risk.
The ChenMed primary care practices at which 100 percent of doctors and staff have received COVID-19 vaccinations include: 100 percent of Chen Senior Medical Centers in Miami; 100 percent of Dedicated Senior Medical Centers in Cincinnati, Houston, Jacksonville, Lakeland, Philadelphia, St. Louis, and Tampa Bay (Bradenton, Clearwater, Largo, Tampa, St. Petersburg);
100 percent of JenCare Senior Medical Centers in Louisville, New Orleans, and Richmond. “We’re making great progress on getting all patient-facing staff vaccinated, and our company-wide goal remains 100 percent,” explains Dr. Lane.
ChenMed has long captured monthly patient feedback using third-party vendors to capture the accurate patient experience data needed to help its primary care physicians keep nurturing outstanding relationships with members.
For the month ending June 30, 2021, the Medallia Experience Cloud survey data shows a robust ChenMed Net Promoter Score (NPS) of 82.9 — substantively higher than many best-in-industry 2021 NPS benchmarks reported by NICE Satmetrix (after collecting more than 65,000 email surveys) for iconic customer brands including Apple (60); Ritz Carlton Hotel (66); USAA (70); Alaska Airlines (71); and Costco Wholesale Corporation (80).
Medalia also surveyed 1,057 ChenMed patients in June, finding:
84 percent said it is very important for their medical care team to be COVID-19 vaccinated.
79 percent (average age 72 years) of seniors reported being more comfortable visiting a medical center when all staff is fully vaccinated.
Noting how NPS can vary by industry, region, or customer characteristics including age, income level, or time with your company, Dr. Syed reports, “Our doctors stay focused on earning trust every day by delivering truly personalized primary care. We give our patients our cell phone numbers. We encourage walk-in appointments. We really practice medicine differently, and the results are outstanding. 1,3-Propanediol, 2-(azidomethyl)-2-[(octyloxy)methyl]- manufacturers Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.” As(OPr-i)3 suppliers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. ethyl 3-(2-(2-carbamoylhydrazineylidene)-2,3-dihydro-1H-inden-1-yl)propanoate vendor & factory.
The ChenMed primary care practices at which 100 percent of doctors and staff have received COVID-19 vaccinations include: 100 percent of Chen Senior Medical Centers in Miami; 100 percent of Dedicated Senior Medical Centers in Cincinnati, Houston, Jacksonville, Lakeland, Philadelphia, St. Louis, and Tampa Bay (Bradenton, Clearwater, Largo, Tampa, St. Petersburg);
100 percent of JenCare Senior Medical Centers in Louisville, New Orleans, and Richmond. “We’re making great progress on getting all patient-facing staff vaccinated, and our company-wide goal remains 100 percent,” explains Dr. Lane.
ChenMed has long captured monthly patient feedback using third-party vendors to capture the accurate patient experience data needed to help its primary care physicians keep nurturing outstanding relationships with members.
For the month ending June 30, 2021, the Medallia Experience Cloud survey data shows a robust ChenMed Net Promoter Score (NPS) of 82.9 — substantively higher than many best-in-industry 2021 NPS benchmarks reported by NICE Satmetrix (after collecting more than 65,000 email surveys) for iconic customer brands including Apple (60); Ritz Carlton Hotel (66); USAA (70); Alaska Airlines (71); and Costco Wholesale Corporation (80).
Medalia also surveyed 1,057 ChenMed patients in June, finding:
84 percent said it is very important for their medical care team to be COVID-19 vaccinated.
79 percent (average age 72 years) of seniors reported being more comfortable visiting a medical center when all staff is fully vaccinated.
Noting how NPS can vary by industry, region, or customer characteristics including age, income level, or time with your company, Dr. Syed reports, “Our doctors stay focused on earning trust every day by delivering truly personalized primary care. We give our patients our cell phone numbers. We encourage walk-in appointments. We really practice medicine differently, and the results are outstanding. 1,3-Propanediol, 2-(azidomethyl)-2-[(octyloxy)methyl]- manufacturers Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.” As(OPr-i)3 suppliers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. ethyl 3-(2-(2-carbamoylhydrazineylidene)-2,3-dihydro-1H-inden-1-yl)propanoate vendor & factory.
